HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3.

Abstract
The molecular interactions between B-cell precursor acute lymphoblastic leukemia (pre-B ALL) cells and stromal cells in the bone marrow that provide microenvironmentally-mediated protection against therapeutic drugs are not well-defined. Galectin-3 (Lgals3) is a multifunctional galactose-binding lectin with reported location in the nucleus, cytoplasm and extracellular space in different cell types. We previously reported that ALL cells co-cultured with stroma contain high levels of Galectin-3. We here establish that, in contrast to more mature B-lineage cancers, Galectin-3 detected in and on the ALL cells originates from stromal cells, which express it on their surface, secrete it as soluble protein and also in exosomes. Soluble and stromal-bound Galectin-3 is internalized by ALL cells, transported to the nucleus and stimulates transcription of endogenous LGALS3 mRNA. When human and mouse ALL cells develop tolerance to different drugs while in contact with protective stromal cells, Galectin-3 protein levels are consistently increased. This correlates with induction of Galectin-3 transcription in the ALL cells. Thus Galectin-3 sourced from stroma becomes supplemented by endogenous Galectin-3 production in the pre-B ALL cells that are under continuous stress from drug treatment. Our data suggest that stromal Galectin-3 may protect ALL cells through auto-induction of Galectin-3 mRNA and tonic NFκB pathway activation. Since endogenously synthesized Galectin-3 protects pre-B ALL cells against drug treatment, we identify Galectin-3 as one possible target to counteract the protective effects of stroma.
AuthorsFei Fei, Eun Ji Joo, Somayeh S Tarighat, Isabelle Schiffer, Helicia Paz, Muller Fabbri, Hisham Abdel-Azim, John Groffen, Nora Heisterkamp
JournalOncotarget (Oncotarget) Vol. 6 Issue 13 Pg. 11378-94 (May 10 2015) ISSN: 1949-2553 [Electronic] United States
PMID25869099 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Blood Proteins
  • Galectin 3
  • Galectins
  • LGALS3 protein, human
  • Lgals3 protein, mouse
  • NF-kappa B
  • RNA, Messenger
Topics
  • Active Transport, Cell Nucleus
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Blood Proteins
  • Cell Line, Tumor
  • Endocytosis
  • Exosomes (metabolism)
  • Galectin 3 (deficiency, genetics, metabolism)
  • Galectins
  • Gene Expression Regulation, Leukemic
  • Humans
  • Mice, Inbred C57BL
  • Mice, Knockout
  • NF-kappa B (metabolism)
  • Paracrine Communication (drug effects)
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, genetics, metabolism, pathology)
  • RNA, Messenger (metabolism)
  • Signal Transduction (drug effects)
  • Stromal Cells (metabolism, pathology)
  • Time Factors
  • Transcription, Genetic
  • Transcriptional Activation
  • Transfection
  • Tumor Microenvironment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: